Olivier Scheidegger1, Daniela Leupold2, Rafael Sauter3, Oliver Findling4,5, Kai Michael Rösler4, Thomas Hundsberger2. 1. Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland. olivier.scheidegger@insel.ch. 2. Department of Neurology, Cantonal Hospital, 9007, St. Gallen, Switzerland. 3. Clinical Trials Unit, Cantonal Hospital, 9007, St. Gallen, Switzerland. 4. Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse, 3010, Bern, Switzerland. 5. Department of Neurology, Cantonal Hospital, 6000, Aarau, Switzerland.
Abstract
INTRODUCTION: Although not curative, enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase enzyme has shown to be effective in the treatment of late-onset Pompe disease (LOPD). For this potentially life-long treatment, little is known on the clinical effect of cessation and resuming ERT. Due to a Swiss supreme court decision on ERT reimbursement, a temporary stop of ERT occurred in our study population. The aim of this study was to report the 36-months follow-up assessments after resuming ERT. METHODS: After resuming ERT, seven patients suffering from genetically and enzymatically confirmed LOPD had periodic, mandatory, prospective assessments of pulmonary function tests, muscle strength summary scores, distances walked in timed walking tests, and patient-reported questionnaires. Data were statistically analyzed for significant differences between time points at ERT cessation, at ERT resuming, and 36 months thereafter. RESULTS: After resuming ERT forced vital capacity (p = 0.007) and distance walked in the 6 min walk test (6-MWT, p = 0.011) significantly increased at 36 months. Compared to before ERT cessation, distance walked in 6-MWT at 36 months still remained significantly lower (p = 0.005). Self-reported scores in the fatigue severity scale significantly declined at 36 months after resuming ERT (p = 0.019). No other functional or reported parameter significantly changed at 36 months after resuming ERT. CONCLUSIONS: Our data suggests that long-term interruption of ERT in LOPD may lead to deterioration of clinical meaningful parameters and quality of life. In addition, a clinical restoration after ERT cessation is possible for most of the LOPD patients within a 36 months follow-up.
INTRODUCTION: Although not curative, enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase enzyme has shown to be effective in the treatment of late-onset Pompe disease (LOPD). For this potentially life-long treatment, little is known on the clinical effect of cessation and resuming ERT. Due to a Swiss supreme court decision on ERT reimbursement, a temporary stop of ERT occurred in our study population. The aim of this study was to report the 36-months follow-up assessments after resuming ERT. METHODS: After resuming ERT, seven patients suffering from genetically and enzymatically confirmed LOPD had periodic, mandatory, prospective assessments of pulmonary function tests, muscle strength summary scores, distances walked in timed walking tests, and patient-reported questionnaires. Data were statistically analyzed for significant differences between time points at ERT cessation, at ERT resuming, and 36 months thereafter. RESULTS: After resuming ERT forced vital capacity (p = 0.007) and distance walked in the 6 min walk test (6-MWT, p = 0.011) significantly increased at 36 months. Compared to before ERT cessation, distance walked in 6-MWT at 36 months still remained significantly lower (p = 0.005). Self-reported scores in the fatigue severity scale significantly declined at 36 months after resuming ERT (p = 0.019). No other functional or reported parameter significantly changed at 36 months after resuming ERT. CONCLUSIONS: Our data suggests that long-term interruption of ERT in LOPD may lead to deterioration of clinical meaningful parameters and quality of life. In addition, a clinical restoration after ERT cessation is possible for most of the LOPD patients within a 36 months follow-up.
Authors: P S Kishnani; D Corzo; M Nicolino; B Byrne; H Mandel; W L Hwu; N Leslie; J Levine; C Spencer; M McDonald; J Li; J Dumontier; M Halberthal; Y H Chien; R Hopkin; S Vijayaraghavan; D Gruskin; D Bartholomew; A van der Ploeg; J P Clancy; R Parini; G Morin; M Beck; G S De la Gastine; M Jokic; B Thurberg; S Richards; D Bali; M Davison; M A Worden; Y T Chen; J E Wraith Journal: Neurology Date: 2006-12-06 Impact factor: 9.910
Authors: Ingemar S J Merkies; Paul I M Schmitz; Frans G A Van Der Meché; Johnny P A Samijn; Pieter A Van Doorn Journal: Muscle Nerve Date: 2002-03 Impact factor: 3.217
Authors: Benedikt Schoser; Andrew Stewart; Steve Kanters; Alaa Hamed; Jeroen Jansen; Keith Chan; Mohammad Karamouzian; Antonio Toscano Journal: J Neurol Date: 2016-07-02 Impact factor: 4.849
Authors: Juna M de Vries; Nadine A M E van der Beek; Wim C J Hop; Francois P J Karstens; John H Wokke; Marianne de Visser; Baziel G M van Engelen; Jan B M Kuks; Anneke J van der Kooi; Nicolette C Notermans; Catharina G Faber; Jan J G M Verschuuren; Michelle E Kruijshaar; Arnold J J Reuser; Pieter A van Doorn; Ans T van der Ploeg Journal: Orphanet J Rare Dis Date: 2012-09-26 Impact factor: 4.123
Authors: Pamela W Duncan; Katherine J Sullivan; Andrea L Behrman; Stanley P Azen; Samuel S Wu; Stephen E Nadeau; Bruce H Dobkin; Dorian K Rose; Julie K Tilson Journal: BMC Neurol Date: 2007-11-08 Impact factor: 2.474
Authors: Ali Al Shehri; Abdullah Al-Asmi; Abdullah Mohammed Al Salti; Abubaker Almadani; Ali Hassan; Ahmed K Bamaga; Edward J Cupler; Jasem Al-Hashel; Majed M Alabdali; Mohammed H Alanazy; Suzan Noori Journal: J Neuromuscul Dis Date: 2022
Authors: G Solé; E Salort-Campana; Y Pereon; T Stojkovic; K Wahbi; P Cintas; D Adams; P Laforet; V Tiffreau; I Desguerre; L I Pisella; A Molon; S Attarian Journal: Rev Neurol (Paris) Date: 2020-04-20 Impact factor: 2.607